Comparing the Improvement of Unstable Vitiligo in Patients Treated by Topical PUVA-Therapy Alone, Topical PUVA-Therapy and Oral Vitamin D, and Topical PUVA-Therapy and Oral Vitamin D and Vitamin B12

Document Type : Original Article (s)


1 Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 General Practitioner, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Skin Diseases and Leishmaniasis Research Center AND Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Student of Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Vitiligo is an acquired multifactorial disorder. Different treatments are used for it and all of them have adverse side-effects. Vitiligo is an autoimmune disease associated with other autoimmune diseases such as hypothyroidism, hyperthyroidism, rheumatoid arthritis, diabetes mellitus, and so on. In these diseases, deficiency of vitamin D and B12 are proposed. So in this study, treatment response and remission in patients taking oral vitamin D and B12 was administered.Methods: 60 patients with active vitiligo were randomly divided into three groups. Group I received topical PUVA for 6 months; group II received topical PUVA and 1 cc oral drops of vitamin D3 daily for 2 months, and then topical PUVA alone for following 4 months; and group III received topical PUVA and 1 cc oral drops of vitamin D3 daily and sublingual tablets of vitamin B12 daily for 2 months, and then treated with topical PUVA for following 4months. Cure rate and side effects were evaluated using Vitiligo Area Scoring Index (VASI) at the third and sixth months.Findings: In each of the three treated groups at different times, the average changes in the area and extent of the lesion were not significantly different. Pruritus and erythema occurred in some patients.Conclusion: In this study, the reduction in the extent and area of lesions in the group receiving vitamin D compared to the control group were higher that indicated the role of vitamin D in preventing progression of active vitiligo.


  1. Bolognia JL, Orlow SJ. Melanocyte biology. Bolognia J, Jorizzo J, Schaffer J. Dermatology. Philadelphi, PA: Saunders; 2012. p. 913.
  2. Alghamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment methods for the evaluation of vitiligo. J Eur Acad Dermatol Venereol 2012; 26(12): 1463-71.
  3. Huggins RH, Schwartz RA, Janniger C. Vitiligo. Acta Dermatovenerol Alp Pannonica Adriat 2005; 14(4): 137-5.
  4. Bonotis K, Pantelis K, Karaoulanis S, Katsimaglis C, Papaliaga M, Zafiriou E, et al. Investigation of factors associated with health-related quality of life and psychological distress in vitiligo. J Dtsch Dermatol Ges 2016; 14(1): 45-9.
  5. Manga P, Elbuluk N, Orlow SJ. Recent advances in understanding vitiligo. F1000Res 2016; 5.
  6. Namazi MR. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected? Pigment Cell Res 2007; 20(5): 360-3.
  7. Silverberg JI, Silverberg NB. Vitiligo disease triggers: psychological stressors preceding the onset of disease. Cutis 2015; 95(5): 255-62.
  8. Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev 2007; 6(3): 138-42.
  9. Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res 2007; 20(4): 271-8.
  10. Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293(6): 730-5.
  11. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev 2006; (1): CD003263.
  12. Shahmoradi Z, Mokhtari F, Faghihi G, Adibi N. Comparing the efficacy of topical clobetasol 0.05% plus 5FU 5% cream vs. topical clobetasol 0.05% alone in treatment of vitiligo. J Res Med Sci 2012; 17(Spec 1): S17-S23.
  13. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2(3): 167-81.
  14. Ortonne JP, Mosher DB, Fitzpatrick TB. Vitiligo and other hypomelanoses of hair and skin. New York, NY: Plenum Medical Book Company; 1983. p. 163-310.
  15. Birlea SA, Costin GE, Norris DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev 2009; 29(3): 514-46.
  16. Pacifico A, Leone G. Photo(chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed 2011; 27(5): 261-77.
  17. Koh MJ, Mok ZR, Chong WS. Phototherapy for the treatment of vitiligo in Asian children. Pediatr Dermatol 2015; 32(2): 192-7.
  18. Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol 2007; 56(2): 274-8.
  19. Kawakami T, Hashimoto T. Disease severity indexes and treatment evaluation criteria in vitiligo. Dermatol Res Pract 2011; 2011: 750342.
  20. Sahni K, Parsad D, Kanwar AJ, Mehta SD. Autologous noncultured melanocyte transplantation for stable vitiligo: can suspending autologous melanocytes in the patients' own serum improve repigmentation and patient satisfaction? Dermatol Surg 2011; 37(2): 176-82.
  21. Sehrawat M, Arora TC, Chauhan A, Kar HK, Poonia A, Jairath V. Correlation of vitamin D levels with pigmentation in vitiligo patients treated with NBUVB therapy. ISRN Dermatol 2014; 2014: 493213.
  22. Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol 2010; 62(6): 937-41.
  23. Finamor DC, Sinigaglia-Coimbra R, Neves LC, Gutierrez M, Silva JJ, Torres LD, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Dermatoendocrinol 2013; 5(1): 222-34.
  24. Parsad D, Kanwar AJ. Topical vitamin D analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009; 22(4): 487-8.
  25. Matin R. Vitiligo in adults and children. BMJ Clin Evid 2011; 2011.
  26. Karadag AS, Tutal E, Ertugrul DT, Akin KO, Bilgili SG. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin Exp Dermatol 2012; 37(1): 62-4.
  27. Don P, Iuga A, Dacko A, Hardick K. Treatment of vitiligo with broadband ultraviolet B and vitamins. Int J Dermatol 2006; 45(1): 63-5.
  28. Gorman S, Judge MA, Hart PH. Immune-modifying properties of topical vitamin D: Focus on dendritic cells and T cells. J Steroid Biochem Mol Biol 2010; 121(1-2): 247-9.
  29. Juzeniene A, Grigalavicius M, Juraleviciute M, Grant WB. Phototherapy and vitamin D. Clin Dermatol 2016; 34(5): 548-55.
  30. Tjioe M, Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol 2002; 82(5): 369-72.
  31. Khurrum H, Alghamdi KM. The relationship between the serum level of vitamin D and vitiligo: A controlled study on 300 subjects. J Cutan Med Surg 2016; 20(2): 139-45.